Therapeutic Role of Ursolic Acid on Ameliorating Hepatic Steatosis and Improving Metabolic Disorders in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Rats
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This stud...
Saved in:
Published in | PloS one Vol. 9; no. 1; p. e86724 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
29.01.2014
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model.
Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress.
These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD. |
---|---|
AbstractList | Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Methodology/Principal Findings Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-[alpha] was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-[alpha] significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. Conclusions/Significance These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-[alpha] involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD. Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD. BackgroundNon-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model.Methodology/principal findingsObese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress.Conclusions/significanceThese results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD. Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-[alpha] was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-[alpha] significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-[alpha] involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD. Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model.BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model.Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress.METHODOLOGY/PRINCIPAL FINDINGSObese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress.These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD.CONCLUSIONS/SIGNIFICANCEThese results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD. Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Methodology/Principal Findings Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. Conclusions/Significance These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD. Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and insulin resistance. Ursolic acid (UA), an ubiquitous triterpenoid with multifold biological roles, is distributed in various plants. This study was conducted to investigate the therapeutic effect and potential mechanisms of UA against hepatic steatosis in a high-fat diet (HFD)-induced obese non-alcoholic fatty liver disease (NAFLD) rat model. Methodology/Principal Findings Obese NAFLD model was established in Sprague-Dawley rats by 8-week HFD feeding. Therapeutic role of UA was evaluated using 0.125%, 0.25%, 0.5% UA-supplemented diet for another 6 weeks. The results from both morphologic and histological detections indicated that UA significantly reversed HFD-induced hepatic steatosis and liver injury. Besides, hepatic peroxisome proliferator-activated receptor (PPAR)-α was markedly up-regulated at both mRNA and protein levels by UA. Knocking down PPAR-α significantly inhibited the anti-steatosis role of UA in vitro. HFD-induced adverse changes in the key genes, which participated in hepatic lipid metabolism, were also alleviated by UA treatment. Furthermore, UA significantly ameliorated HFD-induced metabolic disorders, including insulin resistance, inflammation and oxidative stress. Conclusions/Significance These results demonstrated that UA effectively ameliorated HFD-induced hepatic steatosis through a PPAR-α involved pathway, via improving key enzymes in the controlling of lipids metabolism. The metabolic disorders were accordingly improved with the decrease of hepatic steatosis. Thereby, UA could be a promising candidate for the treatment of NAFLD. |
Audience | Academic |
Author | Sun, Zongxiang Meng, Fanyu Guo, Fuchuan Li, Ying Li, Songtao Sun, Changhao Li, Xiaoxia Meng, Man Wang, Yemei Liao, Xilu |
AuthorAffiliation | Department of Nutrition and Food Hygiene, Harbin Medical University, Harbin, Heilongjiang province, P. R. China CIMA. University of Navarra, Spain |
AuthorAffiliation_xml | – name: Department of Nutrition and Food Hygiene, Harbin Medical University, Harbin, Heilongjiang province, P. R. China – name: CIMA. University of Navarra, Spain |
Author_xml | – sequence: 1 givenname: Songtao surname: Li fullname: Li, Songtao – sequence: 2 givenname: Fanyu surname: Meng fullname: Meng, Fanyu – sequence: 3 givenname: Xilu surname: Liao fullname: Liao, Xilu – sequence: 4 givenname: Yemei surname: Wang fullname: Wang, Yemei – sequence: 5 givenname: Zongxiang surname: Sun fullname: Sun, Zongxiang – sequence: 6 givenname: Fuchuan surname: Guo fullname: Guo, Fuchuan – sequence: 7 givenname: Xiaoxia surname: Li fullname: Li, Xiaoxia – sequence: 8 givenname: Man surname: Meng fullname: Meng, Man – sequence: 9 givenname: Ying surname: Li fullname: Li, Ying – sequence: 10 givenname: Changhao surname: Sun fullname: Sun, Changhao |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24489777$$D View this record in MEDLINE/PubMed |
BookMark | eNqNk9tu1DAQhiNURA_wBggsISG4yOI4iZNwgbQqlK5UqNQDt9bEmey68tqL7VT0fXhQnO0WdasKoVwkmfn-357RzH6yY6zBJHmZ0UmWV9mHKzs4A3qyiuEJpTWvWPEk2cuanKWc0Xzn3vdusu_9FaVlXnP-LNllRVE3VVXtJb8vFuhghUNQkpxZjcT25NJ5q-P_VKqOWEOmS9TKOgjKzMkxrmCEzwNCsF55AqYjs-XK2esx_w0DtGv5Z-Wt69B5ogw5VvNFegQhRjGkM9MNEjvy3Zp0qqVdrAUxHW7IibpGN4oRPJIzCP558rQH7fHF5n2QXB59uTg8Tk9Ov84Opyep5A0LaZtlfUMzyjmnbZtTVtVUYstZVpeYtSVHWpac8T7nPQJ2WcU62tAa2oq3ec_zg-T1re9KWy82DfYiKxpWFow1NBKzW6KzcCVWTi3B3QgLSqwD1s0FuNgdjUIyBgV0dVUiFlLSlqHksmyznJUS2j56fdqcNrRL7CSa4EBvmW5njFqIub0WeUM5Leto8G5j4OzPAX0QS-Ulag0G7bC-dxG7QIvx3m8eoI9Xt6HmEAtQprfxXDmaimlR1XVeFryM1OQRKj4dLpWM09irGN8SvN8SRCbgrzCHwXsxOz_7f_b0xzb79h67QNBhEQc3jrI1fht8db_Tf1t8twYR-HgLSGe9d9gLqQKMPrE0pUVGxbhzd00T486Jzc5FcfFAfOf_T9kfmewxZQ |
CitedBy_id | crossref_primary_10_1016_j_jff_2017_09_056 crossref_primary_10_1016_j_cbi_2017_03_013 crossref_primary_10_1021_acsomega_2c06252 crossref_primary_10_1016_j_apjtm_2016_05_015 crossref_primary_10_1155_2024_5744974 crossref_primary_10_1111_cas_13425 crossref_primary_10_1016_j_bbrc_2017_08_101 crossref_primary_10_3389_fphar_2022_969207 crossref_primary_10_1016_j_phymed_2016_08_003 crossref_primary_10_3389_fmicb_2023_1183598 crossref_primary_10_3390_nu10111719 crossref_primary_10_1016_j_jff_2020_103781 crossref_primary_10_3390_foods11040497 crossref_primary_10_3390_pharmaceutics13060908 crossref_primary_10_3390_foods13142226 crossref_primary_10_1016_j_biopha_2017_08_071 crossref_primary_10_1016_j_jff_2021_104355 crossref_primary_10_1155_2019_8512048 crossref_primary_10_3390_ani14172492 crossref_primary_10_1007_s00204_015_1580_z crossref_primary_10_3390_molecules26237243 crossref_primary_10_3892_etm_2021_10901 crossref_primary_10_3390_antiox13070797 crossref_primary_10_47115_bsagriculture_1194784 crossref_primary_10_1016_j_jff_2015_05_029 crossref_primary_10_1007_s13238_016_0295_0 crossref_primary_10_1016_j_ejphar_2021_174056 crossref_primary_10_3390_molecules28155645 crossref_primary_10_52547_rap_11_30_11 crossref_primary_10_1002_mnfr_201400670 crossref_primary_10_1039_C5FO00083A crossref_primary_10_3390_nano11092196 crossref_primary_10_1007_s10522_023_10024_3 crossref_primary_10_1016_j_ejphar_2014_07_032 crossref_primary_10_1016_j_taap_2017_10_013 crossref_primary_10_3390_antiox11102041 crossref_primary_10_3390_biom15010140 crossref_primary_10_1016_j_jff_2019_03_048 crossref_primary_10_1080_00498254_2016_1234087 crossref_primary_10_3390_ijms20194767 crossref_primary_10_1371_journal_pone_0110711 crossref_primary_10_3390_cancers15082378 crossref_primary_10_3390_foods14030459 crossref_primary_10_3390_biomedicines11102845 crossref_primary_10_1038_cddis_2015_196 crossref_primary_10_4103_ijpvm_ijpvm_317_21 crossref_primary_10_1017_S2040174420000124 crossref_primary_10_4196_kjpp_2018_22_3_235 crossref_primary_10_1016_j_phrs_2023_106925 crossref_primary_10_1097_MCO_0000000000000159 crossref_primary_10_1111_obr_12523 crossref_primary_10_1039_D1FO00924A crossref_primary_10_3390_antiox12040882 crossref_primary_10_1007_s00044_022_02982_z crossref_primary_10_1002_jcb_30496 crossref_primary_10_1016_j_tifs_2016_11_019 crossref_primary_10_3892_mmr_2016_5172 crossref_primary_10_3390_nu9030198 crossref_primary_10_1002_pros_24026 crossref_primary_10_1016_j_fbio_2019_100489 crossref_primary_10_1080_13880209_2016_1214742 crossref_primary_10_1039_D1FO00661D crossref_primary_10_1016_j_fbio_2024_104460 crossref_primary_10_1186_s12906_018_2420_5 crossref_primary_10_2147_JIR_S354878 crossref_primary_10_1186_s12906_022_03794_9 crossref_primary_10_1039_D0SC02922J crossref_primary_10_1080_21623945_2020_1814545 crossref_primary_10_2174_1386207326666230119101011 crossref_primary_10_23736_S1121_421X_20_02738_5 crossref_primary_10_1016_j_phymed_2018_09_011 crossref_primary_10_1002_biof_1319 crossref_primary_10_1517_14728222_2014_944898 crossref_primary_10_1016_j_fitote_2020_104735 crossref_primary_10_2174_0929867330666221209102650 crossref_primary_10_1016_j_jff_2019_103691 crossref_primary_10_1017_S0007114517000228 crossref_primary_10_1155_2020_8370698 crossref_primary_10_3389_fphar_2020_00601 crossref_primary_10_2174_1570163816666190802153319 crossref_primary_10_26599_FSHW_2024_9250079 crossref_primary_10_1016_j_jphs_2019_04_001 crossref_primary_10_3390_nu12010040 crossref_primary_10_1002_crat_201500034 crossref_primary_10_3390_antiox10081161 crossref_primary_10_1002_fsn3_3105 crossref_primary_10_3390_nu12010201 crossref_primary_10_3390_diseases6030080 crossref_primary_10_1016_j_biopha_2018_08_019 crossref_primary_10_1016_j_biopha_2017_11_032 crossref_primary_10_1155_2020_8812634 crossref_primary_10_2174_1871530322666220408123746 crossref_primary_10_1016_j_toxrep_2020_04_005 crossref_primary_10_1089_jmf_2019_0154 crossref_primary_10_1111_jphp_12778 crossref_primary_10_4274_meandros_galenos_2021_32932 crossref_primary_10_1016_j_fct_2020_111537 crossref_primary_10_3748_wjg_v29_i37_5339 crossref_primary_10_47572_muskutd_725703 crossref_primary_10_1097_MEG_0000000000002483 crossref_primary_10_2174_1573407219666221024142326 crossref_primary_10_3390_molecules201119721 crossref_primary_10_1021_acs_jafc_5b06021 crossref_primary_10_1155_2019_9714302 crossref_primary_10_1111_1750_3841_15475 crossref_primary_10_1016_j_phrs_2020_104681 crossref_primary_10_1055_a_2277_4805 crossref_primary_10_1007_s12011_014_0064_y crossref_primary_10_3390_ijms222212162 crossref_primary_10_1007_s10787_022_01038_3 |
Cites_doi | 10.1016/j.numecd.2008.12.015 10.1002/mnfr.200900564 10.1002/hep.20170 10.1046/j.1440-1746.17.s1.10.x 10.2353/ajpath.2006.050953 10.1021/jm900872z 10.3390/molecules14062016 10.1152/ajpgi.00521.2005 10.1016/j.plipres.2008.08.001 10.1371/journal.pone.0037841 10.1002/mnfr.201100392 10.1002/hep.20177 10.1124/jpet.105.085597 10.1021/jf0520342 10.1016/j.phymed.2009.10.021 10.1021/jf802607x 10.1002/hep.24001 10.1016/j.plefa.2003.11.001 10.1093/carcin/21.5.983 10.1089/jmf.2010.0267 10.1210/me.2002-0120 10.1002/mnfr.200700389 10.1002/hep.1840400405 10.1007/s10620-009-1081-0 10.1016/0378-8741(95)90032-2 10.1155/2011/853501 10.2174/156652409787847191 10.1016/j.jhep.2006.02.011 10.1007/s00436-010-1740-2 10.1172/JCI200422422 10.1016/j.ijcard.2013.03.057 10.1093/jn/135.10.2313 10.1055/s-0028-1091986 10.1172/JCI27989 10.1194/jlr.R800089-JLR200 10.1016/S0168-8278(98)80073-1 10.1016/S0016-5085(98)70599-2 10.1007/s11010-005-9053-y 10.1016/j.cld.2004.04.006 10.1002/hep.1840220616 10.4149/gpb_2012_037 10.1503/cmaj.045232 10.1016/j.bbalip.2011.10.016 10.1074/jbc.M112.446575 10.1073/pnas.94.6.2557 10.1002/hep.20783 10.1016/j.jhep.2006.03.005 10.1016/j.bmcl.2011.07.095 10.1371/journal.pone.0039664 10.1371/journal.pone.0039332 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2014 Public Library of Science 2014 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2014 Li et al 2014 Li et al |
Copyright_xml | – notice: COPYRIGHT 2014 Public Library of Science – notice: 2014 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2014 Li et al 2014 Li et al |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
DOI | 10.1371/journal.pone.0086724 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale in Context: Opposing Viewpoints Gale in Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database (ProQuest) Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (Proquest) Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database ProQuest Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Agricultural Science Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) Medicine Biology |
DocumentTitleAlternate | Ursolic Acid Ameliorates NAFLD |
EISSN | 1932-6203 |
ExternalDocumentID | 1492542290 oai_doaj_org_article_c22a4ad875ee4cc0b2ec6c5b1325cabf PMC3906058 3195060981 A478835465 24489777 10_1371_journal_pone_0086724 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NIAAA NIH HHS grantid: R00 AA023002 – fundername: NIAAA NIH HHS grantid: K99 AA023002 |
GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PYCSY RNS RPM SV3 TR2 UKHRP WOQ WOW ~02 ~KM CGR CUY CVF ECM EIF IPNFZ NPM PJZUB PPXIY PQGLB PV9 RIG RZL BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 5PM PUEGO - 02 AAPBV ABPTK ADACO BBAFP KM |
ID | FETCH-LOGICAL-c692t-b11f90106660bb302780ceb62185e1b56e055626f36feaed172d0908ab76b3f63 |
IEDL.DBID | M48 |
ISSN | 1932-6203 |
IngestDate | Fri Nov 26 17:12:45 EST 2021 Wed Aug 27 00:41:55 EDT 2025 Thu Aug 21 18:31:41 EDT 2025 Fri Jul 11 05:13:09 EDT 2025 Fri Jul 25 10:21:41 EDT 2025 Tue Jun 17 21:20:49 EDT 2025 Tue Jun 10 20:42:12 EDT 2025 Fri Jun 27 04:18:27 EDT 2025 Fri Jun 27 04:10:29 EDT 2025 Thu May 22 21:16:32 EDT 2025 Mon Jul 21 05:45:31 EDT 2025 Tue Jul 01 02:58:52 EDT 2025 Thu Apr 24 22:59:48 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c692t-b11f90106660bb302780ceb62185e1b56e055626f36feaed172d0908ab76b3f63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: The authors have declared that no competing interests exist. Conceived and designed the experiments: SL YL CS. Performed the experiments: X. Liao FM YW X. Li MM. Analyzed the data: SL X. Liao. Contributed reagents/materials/analysis tools: FM YW. Wrote the paper: SL YL CS. Supplementary experiments for revising the manuscript: ZS FG. |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0086724 |
PMID | 24489777 |
PQID | 1492542290 |
PQPubID | 1436336 |
PageCount | e86724 |
ParticipantIDs | plos_journals_1492542290 doaj_primary_oai_doaj_org_article_c22a4ad875ee4cc0b2ec6c5b1325cabf pubmedcentral_primary_oai_pubmedcentral_nih_gov_3906058 proquest_miscellaneous_1494302040 proquest_journals_1492542290 gale_infotracmisc_A478835465 gale_infotracacademiconefile_A478835465 gale_incontextgauss_ISR_A478835465 gale_incontextgauss_IOV_A478835465 gale_healthsolutions_A478835465 pubmed_primary_24489777 crossref_citationtrail_10_1371_journal_pone_0086724 crossref_primary_10_1371_journal_pone_0086724 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-01-29 |
PublicationDateYYYYMMDD | 2014-01-29 |
PublicationDate_xml | – month: 01 year: 2014 text: 2014-01-29 day: 29 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, USA |
PublicationTitle | PloS one |
PublicationTitleAlternate | PLoS One |
PublicationYear | 2014 |
Publisher | Public Library of Science Public Library of Science (PLoS) |
Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
References | RA Srivastava (ref38) 2006; 285 S Ferreira Dda (ref29) 2010; 106 P Tessari (ref50) 2009; 19 Z Liu (ref21) 2012; 7 E Ip (ref47) 2004; 39 T Fukao (ref43) 2004; 70 MS Rao (ref5) 2004; 40 SQ Yang (ref8) 1997; 94 MR Teli (ref9) 1995; 22 SK Erickson (ref20) 2009; 50 J Liu (ref12) 1995; 49 H Tilg (ref46) 2010; 52 CP Day (ref4) 1998; 114 G Musso (ref27) 2009; 48 A Laurent (ref53) 2004; 39 G Svegliati-Baroni (ref28) 2006; 169 F Sun (ref39) 2010; 17 ref6 P Lefebvre (ref7) 2006; 116 C Le May (ref42) 2005; 135 VS Rao (ref15) 2011; 14 N Rafiq (ref10) 2008; 28 I Pineda Torra (ref32) 2003; 17 R Hu (ref22) 2012; 7 SA Polyzos (ref49) 2009; 9 Y Ikeda (ref13) 2008; 52 LA Adams (ref48) 2005; 172 JF Silverman (ref19) 1990; 85 JK Reddy (ref30) 2006; 290 C Genet (ref34) 2010; 53 G Musso (ref40) 2009; 48 ref2 N Lu (ref24) 2008; 56 Y Li (ref14) 2010; 54 RH McMahan (ref36) 2013; 288 F Guo (ref25) 2011; 55 S Jager (ref11) 2009; 14 A Lonardo (ref51) 2006; 44 JD Browning (ref41) 2004; 114 B Jayaprakasam (ref18) 2006; 54 P Angulo (ref1) 2002; 17 K Hensley (ref52) 2000; 21 X Chen (ref35) 2011; 2011 SD Kunkel (ref16) 2012; 7 S Fiorucci (ref33) 2005; 315 OF James (ref3) 1998; 29 Y Jia (ref31) 2011; 21 JK Reddy (ref26) 2006; 290 A Sundaresan (ref17) 2012; 31 S Li (ref23) 2013; 168 XX Yu (ref37) 2005; 42 JR Lewis (ref44) 2010; 55 JW Haukeland (ref45) 2006; 44 PLoS One. 2014;9(3):e92364 |
References_xml | – volume: 19 start-page: 291 year: 2009 ident: ref50 article-title: Hepatic lipid metabolism and non-alcoholic fatty liver disease publication-title: Nutr Metab Cardiovasc Dis doi: 10.1016/j.numecd.2008.12.015 – volume: 54 start-page: 1609 year: 2010 ident: ref14 article-title: Ursolic acid stimulates lipolysis in primary-cultured rat adipocytes publication-title: Mol Nutr Food Res doi: 10.1002/mnfr.200900564 – volume: 39 start-page: 1286 year: 2004 ident: ref47 article-title: Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice publication-title: Hepatology doi: 10.1002/hep.20170 – volume: 17 start-page: S186 year: 2002 ident: ref1 article-title: Non-alcoholic fatty liver disease publication-title: J Gastroenterol Hepatol doi: 10.1046/j.1440-1746.17.s1.10.x – volume: 169 start-page: 846 year: 2006 ident: ref28 article-title: A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury publication-title: Am J Pathol doi: 10.2353/ajpath.2006.050953 – volume: 53 start-page: 178 year: 2010 ident: ref34 article-title: Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes publication-title: J Med Chem doi: 10.1021/jm900872z – volume: 14 start-page: 2016 year: 2009 ident: ref11 article-title: Pentacyclic triterpene distribution in various plants - rich sources for a new group of multi-potent plant extracts publication-title: Molecules doi: 10.3390/molecules14062016 – volume: 290 start-page: G852 year: 2006 ident: ref30 article-title: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation publication-title: Am J Physiol Gastrointest Liver Physiol doi: 10.1152/ajpgi.00521.2005 – volume: 48 start-page: 1 year: 2009 ident: ref40 article-title: Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD) publication-title: Prog Lipid Res doi: 10.1016/j.plipres.2008.08.001 – volume: 7 start-page: e37841 year: 2012 ident: ref21 article-title: A potent lead induces apoptosis in pancreatic cancer cells publication-title: PLoS One doi: 10.1371/journal.pone.0037841 – volume: 55 start-page: 1809 year: 2011 ident: ref25 article-title: Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters publication-title: Mol Nutr Food Res doi: 10.1002/mnfr.201100392 – volume: 39 start-page: 1277 year: 2004 ident: ref53 article-title: Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis publication-title: Hepatology doi: 10.1002/hep.20177 – volume: 315 start-page: 58 year: 2005 ident: ref33 article-title: Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.105.085597 – volume: 54 start-page: 243 year: 2006 ident: ref18 article-title: Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas) publication-title: J Agric Food Chem doi: 10.1021/jf0520342 – volume: 17 start-page: 669 year: 2010 ident: ref39 article-title: Osthol regulates hepatic PPAR alpha-mediated lipogenic gene expression in alcoholic fatty liver murine publication-title: Phytomedicine doi: 10.1016/j.phymed.2009.10.021 – volume: 56 start-page: 11526 year: 2008 ident: ref24 article-title: Gossypin up-regulates LDL receptor through activation of ERK pathway: a signaling mechanism for the hypocholesterolemic effect publication-title: J Agric Food Chem doi: 10.1021/jf802607x – volume: 52 start-page: 1836 year: 2010 ident: ref46 article-title: Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis publication-title: Hepatology doi: 10.1002/hep.24001 – volume: 290 start-page: G852 year: 2006 ident: ref26 article-title: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation publication-title: American journal of physiology Gastrointestinal and liver physiology doi: 10.1152/ajpgi.00521.2005 – volume: 70 start-page: 243 year: 2004 ident: ref43 article-title: Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry publication-title: Prostaglandins Leukot Essent Fatty Acids doi: 10.1016/j.plefa.2003.11.001 – volume: 21 start-page: 983 year: 2000 ident: ref52 article-title: Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria publication-title: Carcinogenesis doi: 10.1093/carcin/21.5.983 – volume: 14 start-page: 1375 year: 2011 ident: ref15 article-title: Ursolic acid, a pentacyclic triterpene from Sambucus australis, prevents abdominal adiposity in mice fed a high-fat diet publication-title: J Med Food doi: 10.1089/jmf.2010.0267 – volume: 17 start-page: 259 year: 2003 ident: ref32 article-title: Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor publication-title: Mol Endocrinol doi: 10.1210/me.2002-0120 – volume: 52 start-page: 26 year: 2008 ident: ref13 article-title: Ursolic acid: an anti- and pro-inflammatory triterpenoid publication-title: Mol Nutr Food Res doi: 10.1002/mnfr.200700389 – volume: 85 start-page: 1349 year: 1990 ident: ref19 article-title: Liver pathology in morbidly obese patients with and without diabetes publication-title: Am J Gastroenterol – volume: 40 start-page: 783 year: 2004 ident: ref5 article-title: PPARalpha in the pathogenesis of fatty liver disease publication-title: Hepatology doi: 10.1002/hep.1840400405 – volume: 55 start-page: 560 year: 2010 ident: ref44 article-title: Nonalcoholic fatty liver disease: a review and update publication-title: Dig Dis Sci doi: 10.1007/s10620-009-1081-0 – volume: 49 start-page: 57 year: 1995 ident: ref12 article-title: Pharmacology of oleanolic acid and ursolic acid publication-title: J Ethnopharmacol doi: 10.1016/0378-8741(95)90032-2 – volume: 2011 start-page: 853501 year: 2011 ident: ref35 article-title: TGR5: a novel target for weight maintenance and glucose metabolism publication-title: Exp Diabetes Res doi: 10.1155/2011/853501 – volume: 9 start-page: 299 year: 2009 ident: ref49 article-title: Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines publication-title: Curr Mol Med doi: 10.2174/156652409787847191 – volume: 44 start-page: 1167 year: 2006 ident: ref45 article-title: Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2 publication-title: J Hepatol doi: 10.1016/j.jhep.2006.02.011 – volume: 106 start-page: 985 year: 2010 ident: ref29 article-title: Trypanocidal activity and acute toxicity assessment of triterpene acids publication-title: Parasitol Res doi: 10.1007/s00436-010-1740-2 – volume: 114 start-page: 147 year: 2004 ident: ref41 article-title: Molecular mediators of hepatic steatosis and liver injury publication-title: J Clin Invest doi: 10.1172/JCI200422422 – volume: 168 start-page: 2548 year: 2013 ident: ref23 article-title: Calcium supplementation increases circulating cholesterol by reducing its catabolism via GPER and TRPC1-dependent pathway in estrogen deficient women publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2013.03.057 – volume: 135 start-page: 2313 year: 2005 ident: ref42 article-title: Fatty acids induce L-CPT I gene expression through a PPARalpha-independent mechanism in rat hepatoma cells publication-title: J Nutr doi: 10.1093/jn/135.10.2313 – volume: 28 start-page: 427 year: 2008 ident: ref10 article-title: Effects of weight loss on nonalcoholic fatty liver disease publication-title: Semin Liver Dis doi: 10.1055/s-0028-1091986 – volume: 48 start-page: 1 year: 2009 ident: ref27 article-title: Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD) publication-title: Progress in lipid research doi: 10.1016/j.plipres.2008.08.001 – volume: 116 start-page: 571 year: 2006 ident: ref7 article-title: Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis publication-title: J Clin Invest doi: 10.1172/JCI27989 – volume: 50 year: 2009 ident: ref20 article-title: Nonalcoholic fatty liver disease publication-title: J Lipid Res doi: 10.1194/jlr.R800089-JLR200 – volume: 29 start-page: 495 year: 1998 ident: ref3 article-title: Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance publication-title: J Hepatol doi: 10.1016/S0168-8278(98)80073-1 – volume: 114 start-page: 842 year: 1998 ident: ref4 article-title: Steatohepatitis: a tale of two “hits”? publication-title: Gastroenterology doi: 10.1016/S0016-5085(98)70599-2 – volume: 285 start-page: 35 year: 2006 ident: ref38 article-title: Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice publication-title: Mol Cell Biochem doi: 10.1007/s11010-005-9053-y – ident: ref2 doi: 10.1016/j.cld.2004.04.006 – volume: 22 start-page: 1714 year: 1995 ident: ref9 article-title: The natural history of nonalcoholic fatty liver: a follow-up study publication-title: Hepatology doi: 10.1002/hep.1840220616 – volume: 31 start-page: 323 year: 2012 ident: ref17 article-title: Ursolic acid and rosiglitazone combination alleviates metabolic syndrome in high fat diet fed C57BL/6J mice publication-title: General physiology and biophysics doi: 10.4149/gpb_2012_037 – volume: 172 start-page: 899 year: 2005 ident: ref48 article-title: Nonalcoholic fatty liver disease publication-title: CMAJ doi: 10.1503/cmaj.045232 – ident: ref6 doi: 10.1016/j.bbalip.2011.10.016 – volume: 288 start-page: 11761 year: 2013 ident: ref36 article-title: Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease publication-title: J Biol Chem doi: 10.1074/jbc.M112.446575 – volume: 94 start-page: 2557 year: 1997 ident: ref8 article-title: Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.94.6.2557 – volume: 42 start-page: 362 year: 2005 ident: ref37 article-title: Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice publication-title: Hepatology doi: 10.1002/hep.20783 – volume: 44 start-page: 1196 year: 2006 ident: ref51 article-title: ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis publication-title: J Hepatol doi: 10.1016/j.jhep.2006.03.005 – volume: 21 start-page: 5876 year: 2011 ident: ref31 article-title: Ursolic acid is a PPAR-alpha agonist that regulates hepatic lipid metabolism publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2011.07.095 – volume: 7 start-page: e39664 year: 2012 ident: ref22 article-title: 6-Shogaol induces apoptosis in human hepatocellular carcinoma cells and exhibits anti-tumor activity in vivo through endoplasmic reticulum stress publication-title: PLoS One doi: 10.1371/journal.pone.0039664 – volume: 7 start-page: e39332 year: 2012 ident: ref16 article-title: Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease publication-title: PLoS One doi: 10.1371/journal.pone.0039332 – reference: - PLoS One. 2014;9(3):e92364 |
SSID | ssj0053866 |
Score | 2.505381 |
Snippet | Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity, diabetes, and... Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity,... BackgroundNon-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity,... Background Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases around the world, and is closely associated with obesity,... |
SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | e86724 |
SubjectTerms | Acid resistance Acids Animals Biology CD36 Antigens - genetics CD36 Antigens - metabolism Diabetes mellitus Diacylglycerol O-Acyltransferase - genetics Diacylglycerol O-Acyltransferase - metabolism Diet Diet, High-Fat Dietary Fats - adverse effects Disorders Enzymes Fatty liver Fatty Liver - drug therapy Fatty Liver - etiology Fatty Liver - metabolism Fatty Liver - pathology Gene Expression Health aspects High fat diet Insulin Insulin Resistance Laboratory animals Lipase - genetics Lipase - metabolism Lipid metabolism Lipid Metabolism - drug effects Lipids Liver Liver - drug effects Liver - metabolism Liver - pathology Liver diseases Male Medicine Metabolic disorders Metabolism mRNA Non-alcoholic Fatty Liver Disease Obesity Obesity - drug therapy Obesity - etiology Obesity - metabolism Obesity - pathology Oxidation resistance Oxidative stress Peroxisome proliferator-activated receptors Plants (botany) PPAR alpha - antagonists & inhibitors PPAR alpha - genetics PPAR alpha - metabolism Rats Rats, Sprague-Dawley RNA RNA, Messenger - genetics RNA, Messenger - metabolism RNA, Small Interfering - genetics RNA, Small Interfering - metabolism Rodents Steatosis Triterpenes - pharmacology Ursolic Acid |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELbQnrggyl8DBQxCAg6mSZw48bEgqoIESNCi3iLbsdtIW2dFsgfehwdlJnFCgyqVA8eNx7vZmfF4xp75hpAXZWkTnRvJVJpKPLpRTGWFYFYWVkoHMbTBo4FPn8XRSfbxND-91OoLc8JGeOCRcfsmTVWmanCrrc2MiXVqjTC5higqN0o7tL6w503B1GiDYRULEQrleJHsB7m82bTeIqCpKNJssRENeP2zVV5t1m13lcv5d-bkpa3o8Da5FXxIejC--w65Yf0dshNWaUdfBSjp13fJr-M_5VUUEwlp6-gWW2TDZ2Wamraeqgu7bgZN8Gf03GKKtaEo_L7tmo4qX9NmOnqgF7YHtcHpdcDt7GjjKaIeM6d6eGp7BnE-aExNfeuZGnvwwgQY7n_SNSaC0HAvROFXu3vk5PD98bsjFvoyMCNk2jOdJA6zOiDyibXGi88yNlYL8BZylLywiNCTCseFs8rW4CPVsYxLpQuhuRP8PlnBC9hdQlUB4aEoZRnLMsscV9pwnSsOElcJ-EYR4ZOQKhNAy7F3xroabuIKCF5Gnlco2iqINiJsnrUZQTuuoX-L8p9pEXJ7eACKWAVFrK5TxIg8Re2pxvrV2XBUB9iggGPP-Yg8HygQdsNjXs-Z2nZd9eHL938g-vZ1QfQyELkW2GFUqKWA_4RwXgvKvQUlGA-zGN5FXZ-40kEkKNM8wyYAMHPS_6uHn83D-KWYq-dtux1oMo4110DzYFwuM2fBmSwh4igiUiwW0oL1yxHfnA-o51zGeIX_8H_I6hG5CY4vpl-xVO6RVf9jax-Dc9nrJ4Md-Q1mEn1k priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nj9MwELWgXLgglq8NLGAQEnAwm8SJk5xQQZSC2EUqW7S3yHacbqUSl0164P_wQ5lJnCxBK-DYeFwlHs94xn5-Q8izNDWBinXGZBhmuHUjmYwSwUyWmCwrIYfWuDVwdCzmy-jjaXzqNtxqB6vsfWLrqAurcY_8MEAWvQjZyV9vvzOsGoWnq66ExlVyLYCVBiFd6ex974nBloVw1-V4Ehw67bza2sogralIwmi0HLWs_YNvnmw3tr4s8PwTP_nbgjS7SW64SJJOO9XvkSumukX2nK3W9IUjlH55m_w8ubhkRRd2Y6gt6RILZcPvqV4X1FZ0-s1s1u18qFZ0bhBorSmifRtbr2sqq4IOGxD0yDQwebB7z95Z03VFETTCZrKBp6ZhWBVEm4Ie24pNu0q80AGamx_0E8JBsDOeDtGFbOo7ZDl7d_J2zlx1BqZFFjZMBUGJ2A7If3yl8Pgz9bVRAmKGGPUvDPL0hKLkojTSFBApFX7mp1IlQvFS8LtkUoEm9gmVCSSJIs1SP0ujqORSaa5iySNZyAAiJI_wXkm5dtTlWEFjk7fncQmkMN2Y56ja3KnWI2zote2oO_4h_wb1P8gi8Xb7wJ6vcmfHuQ5DCa8FWZ4xkda-Co0WOlaQ1MdaqtIjj3H25N0t1sF95FMsU8Cx8rxHnrYSSL5RIbpnJXd1nX_4_PU_hL4sRkLPnVBpYTi0dDcq4JuQ1GskeTCSBBeiR837ONf7UanzC2ODnv38v7z5ydCMf4qIvcrYXSsTcbx5DTL3OnMZRhZCyhTyjsQjyciQRkM_bqnWZy33Oc98PMi___fXekCuQ2CL8CoWZgdk0pzvzEMIHhv1qPUQvwCaLXCw priority: 102 providerName: ProQuest |
Title | Therapeutic Role of Ursolic Acid on Ameliorating Hepatic Steatosis and Improving Metabolic Disorders in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Rats |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24489777 https://www.proquest.com/docview/1492542290 https://www.proquest.com/docview/1494302040 https://pubmed.ncbi.nlm.nih.gov/PMC3906058 https://doaj.org/article/c22a4ad875ee4cc0b2ec6c5b1325cabf http://dx.doi.org/10.1371/journal.pone.0086724 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe27oUXxPhaxygGIQEPmfLpJA8IbVPLQNpAY0V9i2zH6SJ1TmlSib3w1_CHcpc4gaBO8BKp8TlJ78O-s8-_I-RlFClHBDK2uOvGuHTDLe6HzFJxqOI4gxha4tLA2Tk7nfofZ8Fsi7Q1Ww0Dy42hHdaTmq4Wh9-_3bwDg39bV20InbbT4bLQCuFKWej622QH5qYQaxqc-d2-Alg3Y-YA3W09ER4YYhbwi8LeXFVD-ncD92C5KMpNXunfyZV_zFaTe-SucTPpUaMXu2RL6ftk1xhySV8btOk3D8jPy98nsCjmGtIio2usog2_ucxTWmjKr9Uir5VFz-mVwixsSVE_qqLMS8p1SvN2dYJeqwo0C7unBtqzpLmmCIxsZbyCu6qycp2CUqVUF9riTZle6ADN1Q1dYK4INVtHFN5aPiTTyfjy5NQypRssyWK3soTjZJj4AcGRLQTujUa2VIKBQxGgcjCFID4uyzyWKa5SkFRqx3bERciElzHvERnAB6g9QnkI0mBRHNlx5PuZx4X0RMA9n6fcAfdpSLxWSIk0uOZYXmOR1Jt1IcQ3Dc8TlHJipDwkVtdr2eB6_IP-GOXf0SIqd32jWM0TY-SJdF0OnwUhoFK-lLZwlWQyEBDxB5KLbEieofYkzRHXbmxJjrCGgYdl6YfkRU2ByBwaU3_mfF2WyYdPX_-D6MtFj-iVIcoKYIfk5rgF_CdE_OpRHvQoYXyRveY91PWWKyUEi7Eb-FgnAHq2-r-5-XnXjA_FdD6tinVN43t4LBtoHjfm0nG2Nb4hCXuG1GN9v0XnVzUwuhfbuMu_f-szn5A74PBi2pXlxgdkUK3W6ik4lZUYke1wFsI1OnHwOnk_IjvH4_PPF6N6mWZUjyN4_TH-BbwDfzs |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELaWcoALYnltYWENAgEHs0mcOskBofIoLdsWaWlXewu245RKJSmbVGj_D2d-IzN5LUEr4LLHxuMo9YznYc98Q8hj3ze26umASccJ8OhGMul6gpnAM0EQQwyt8WhgMhXDufvhuHe8RX7WtTCYVlnrxEJRR6nGM_J9G1H0XEQnf7X-xrBrFN6u1i00SrE4MKffIWTLXo7eAn-fOM7g3ezNkFVdBZgWgZMzZdsx5iSA324phdd2vqWNEmDrevjdwiC-jCNiLmIjTQQWPrICy5fKE4rHgsN7L5HLLgdLjpXpg_e15gfdIURVnsc9e7-ShhfrNDEIoyo8x22Zv6JLQGMLOutVmp3n6P6Zr_mbARxcJ9cqz5X2S1HbJlsmuUG2K92Q0WcVgPXzm-TH7Kyoix6mK0PTmM6xMTf87utlRNOE9r-a1bKQv2RBhwYTuzXF7OI8zZYZlUlEmwMPOjE5CCtOr9FCM7pMKCapsIHM4anJGXYh0Sai0zRh_bLzL0yA4fyUjjH9BCfjbRQ9lHl2i8wvhG-3SScBTuwQKj0ISoUf-Fbgu27MpdJc9SR3ZSRt8Mi6hNdMCnUFlY4dO1Zhcf_nQchUrnmIrA0r1nYJa2atS6iQf9C_Rv43tAj0XTxITxZhpTdC7TgSPguiSmNcrS3lGC10T9nc6Wmp4i7ZQ-kJy6rZRl2FfWyLwLHTfZc8KigQ7CPBbKKF3GRZOPp49B9Enw5bRE8rojiF5dCyquCA_4QgYi3K3RYlqCzdGt5BWa9XJQvPNjfMrOX__OGHzTC-FDMEE5NuChqXY6U30Nwpt0uzsuDC-hDneF3itTZSa-nbI8nyS4G1zgMLEwfu_v2z9siV4WwyDsej6cE9chWcakztYk6wSzr5ycbcB8c1Vw8KbUHJ54tWT78A-XKsIA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGkRAviPFvhcEMAgEPoYmdOskDQmWjatlWUFmnvQXbcUqlkpQlFdr34VPw6bjLvxE0AS97bHyOGt_5fGf__DtCnvq-cVRfB5ZkLMCtG2lJ1xOWCTwTBDHk0Bq3Bg4nYjRz35_0TzbIz_ouDMIqa59YOOoo1bhH3nOQRc9FdvJeXMEiPu4N36y-WVhBCk9a63IapYnsm7PvkL5lr8d7oOtnjA3fHe2OrKrCgKVFwHJLOU6M-ASI4W2l8AjPt7VRAta9Pn6DMMg1w0TMRWykiWC1j-zA9qXyhOKx4PDeK-Sqxz0f55i_28BLwI8IUV3V457Tqyzj1SpNDFKqCo-5raWwqBjQrAud1TLNLgp6_8Ru_rYYDm-SG1UUSwel2W2SDZPcIpuVn8joi4rM-uVt8uPo_IIXnaZLQ9OYzrBIN_we6EVE04QOvprlorDFZE5HBkHemiLSOE-zRUZlEtFm84MemhwMF7vXzKEZXSQUASvWUObw1OQWViTRJqKTNLEGZRVg6ADN-Rk9QCgKdsaTKTqVeXaHzC5Fb3dJJwFNbBEqPUhQhR_4duC7bsyl0lz1JXdlJB2IzrqE10oKdUWbjtU7lmFxFuhB-lSOeYiqDSvVdonV9FqVtCH_kH-L-m9kkfS7eJCezsPKh4SaMQl_CzJMY1ytbcWMFrqvHM76Wqq4S3bQesLyBm3jusIBlkjgWPW-S54UEkj8keAUmst1loXjD8f_IfRp2hJ6XgnFKQyHltVtDvgmJBRrSW63JMF96VbzFtp6PSpZeD7RoWdt_xc3P26a8aWIFkxMui5kXI63vkHmXjldmpGFcNaHnMfrEq81kVpD325JFl8K3nUe2AgiuP_3v7VDroFjCg_Gk_0H5DrE14jysliwTTr56do8hBg2V48KZ0HJ58v2Tr8Ajh-wIQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+role+of+ursolic+acid+on+ameliorating+hepatic+steatosis+and+improving+metabolic+disorders+in+high-fat+diet-induced+non-alcoholic+fatty+liver+disease+rats&rft.jtitle=PloS+one&rft.au=Li%2C+Songtao&rft.au=Liao%2C+Xilu&rft.au=Meng%2C+Fanyu&rft.au=Wang%2C+Yemei&rft.date=2014-01-29&rft.eissn=1932-6203&rft.volume=9&rft.issue=1&rft.spage=e86724&rft_id=info:doi/10.1371%2Fjournal.pone.0086724&rft_id=info%3Apmid%2F24489777&rft.externalDocID=24489777 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |